Although KRAS mutations are detectable in a high proportion of PDACs, almost in half of colorectal adenocarcinomas (CRC) and in approximately 30% of lung adenocarcinomas, higher response rates for KRAS-targeted therapy are so far restricted to lung cancer [18]. This evidence concerns the gene KRAS and colorectal adenocarcinoma.